{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir+Tablets&page=2", "query": { "intervention": "Cabotegravir Tablets", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 37, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir+Tablets&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir+Tablets&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T17:36:29.768Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04371380", "title": "Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Tablets", "type": "DRUG" }, { "name": "Rilpivirine Tablets", "type": "DRUG" }, { "name": "Cabotegravir extended release suspension for injection (long-acting)", "type": "DRUG" }, { "name": "Rilpivirine extended release suspension for injection (long-acting)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 15, "start_date": "2020-09-16", "completion_date": "2021-12-26", "has_results": true, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-09-30T17:36:29.768Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04371380" }, { "nct_id": "NCT07682961", "title": "Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lenacapavir", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" }, { "name": "Teropavimab", "type": "DRUG" }, { "name": "Zinlirvimab", "type": "DRUG" }, { "name": "Cabotegravir", "type": "DRUG" }, { "name": "Rilpivirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2026-07-14", "completion_date": "2033-03", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-30T17:36:29.768Z", "location_count": 16, "location_summary": "San Francisco, California • DeLand, Florida • Fort Lauderdale, Florida + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Miami Gardens", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07682961" }, { "nct_id": "NCT01648257", "title": "Relative Bioavailability Study of GSK1265744 Formulations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infections, Human Immunodeficiency Virus and Hepatitis" ], "interventions": [ { "name": "GSK1265744 Na Salt Tablets", "type": "DRUG" }, { "name": "GSK1265744 Free Acid Nanomilled Capsules", "type": "DRUG" }, { "name": "GSK1265744 Free Acid Micronized Capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 18, "start_date": "2012-08", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2016-08-12", "last_synced_at": "2026-09-30T17:36:29.768Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01648257" }, { "nct_id": "NCT05514509", "title": "A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "APRETUDE", "type": "DRUG" }, { "name": "Cabotegravir tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 370, "start_date": "2022-10-28", "completion_date": "2025-09-02", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-09-30T17:36:29.768Z", "location_count": 22, "location_summary": "Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 13 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05514509" }, { "nct_id": "NCT03299049", "title": "Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Tablets", "type": "DRUG" }, { "name": "Rilpivirine Tablets", "type": "DRUG" }, { "name": "Cabotegravir Injectable Suspension", "type": "DRUG" }, { "name": "Rilpivirine Injectable Suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1049, "start_date": "2017-10-27", "completion_date": "2029-12-31", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-09-30T17:36:29.768Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03299049" }, { "nct_id": "NCT02799264", "title": "A Study to Evaluate the Effect of High Fat Meal on Cabotegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Cabotegravir 30 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2016-06", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-09-30T17:36:29.768Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02799264" }, { "nct_id": "NCT05502341", "title": "Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Bictegravir", "type": "DRUG" }, { "name": "Lenacapavir", "type": "DRUG" }, { "name": "BIC/LEN FDC", "type": "DRUG" }, { "name": "Stable Baseline Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 689, "start_date": "2022-08-16", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-30T17:36:29.768Z", "location_count": 40, "location_summary": "Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05502341" }, { "nct_id": "NCT05374525", "title": "A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "APRETUDE", "type": "DRUG" }, { "name": "Cabotegravir OLI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 287, "start_date": "2022-05-18", "completion_date": "2024-08-08", "has_results": true, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-09-30T17:36:29.768Z", "location_count": 17, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05374525" }, { "nct_id": "NCT04542070", "title": "A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Tablets", "type": "DRUG" }, { "name": "Cabotegravir Injectable Suspension (CAB LA)", "type": "DRUG" }, { "name": "Rilpivirine Tablets", "type": "DRUG" }, { "name": "Rilpivirine Injectable Suspension (RPV LA)", "type": "DRUG" }, { "name": "BIKTARVY Tablets (BIK)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 687, "start_date": "2020-11-09", "completion_date": "2023-04-17", "has_results": true, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-09-30T17:36:29.768Z", "location_count": 41, "location_summary": "Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04542070" }, { "nct_id": "NCT02345707", "title": "Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Cabotegravir 30 mg current formulation", "type": "DRUG" }, { "name": "Cabotegravir 30 mg micronized new formulation 500 M", "type": "DRUG" }, { "name": "Cabotegravir 30 mg unmicronized new formulation 500 U", "type": "DRUG" }, { "name": "Cabotegravir 30 mg micronized new formulation 650 M", "type": "DRUG" }, { "name": "Cabotegravir 30 mg unmicronized new formulation 650 U", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2015-03", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2015-07-13", "last_synced_at": "2026-09-30T17:36:29.768Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02345707" } ] }